Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Everest Medicines Limited
  6. Summary
    1952   KYG3224E1061

EVEREST MEDICINES LIMITED

(1952)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
38.25 35.4 34 33.4 33.7 Last
396500 3404500 1086327 429030 330293 Volume
-3.53% -7.45% -3.95% -1.76% +0.90% Change
Estimated financial data (e)
Sales 2021 1,92 M 0,30 M 0,30 M
Net income 2021 -1 046 M -164 M -164 M
Net cash position 2021 3 029 M 475 M 475 M
P/E ratio 2021 -7,69x
Yield 2021 -
Sales 2022 780 M 122 M 122 M
Net income 2022 -586 M -91,9 M -91,9 M
Net cash position 2022 1 808 M 284 M 284 M
P/E ratio 2022 -12,3x
Yield 2022 -
Capitalization 8 180 M 1 283 M 1 283 M
EV / Sales 2021 2 687x
EV / Sales 2022 8,17x
Nbr of Employees 227
Free-Float 100%
More Financials
Company
Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The... 
Sector
Pharmaceuticals
Calendar
03/21Earnings Release
More about the company
Ratings of Everest Medicines Limited
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about EVEREST MEDICINES LIMITED
11/30Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Stra..
CI
11/23Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China..
PR
11/10Everest Medicines' Phase 2b Trial in China of Breast Cancer Drug Meets Study Endpoint; ..
MT
11/08Everest Medicines Eyes Buyback of Nearly $13 Million Worth of Shares
MT
11/07Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
PR
10/31Everest Medicines Announces Share Repurchase Transaction Details
PR
10/09Certain Shares of Everest Medicines Limited are subject to a Lock-Up Agreement Ending o..
CI
10/04Everest Medicines Limited commences an Equity Buyback Plan for 29,684,786 shares, repre..
CI
09/30EVEREST MEDICINES' : New Drug Application for Complicated Intra-Abdominal Infections Treat..
MT
09/29Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaT..
CI
09/29EVEREST MEDICINES : Initiates Submission of New Drug Application in Hong Kong for XeravaTM..
PR
09/29Everest Medicines Limited Business Update on the Submission of New Drug Application in ..
CI
09/24EVEREST MEDICINES : Wins Nod to Begin Clinical Trial of Novel Bacterial Infections Treatme..
MT
09/24EVEREST MEDICINES : Announces Approval of Investigational New Drug Application by China NM..
PR
09/24Everest Medicines Limited Receives Approval for Investigational New Drug Application fo..
CI
More news
News in other languages on EVEREST MEDICINES LIMITED
11/10L'essai de phase 2b d'Everest Medicines en Chine sur un médicament contre le cancer du ..
11/08Everest Medicines envisage de racheter des actions pour une valeur de près de 13 millio..
09/23AbCellera Biologics et Everest Medicines concluent un accord de collaboration et de lic..
07/12Everest Medicines signe un partenariat commercial stratégique avec Tencent
06/23Everest Medicines attribue près de 3 millions d'actions à ses employés
More news
Analyst Recommendations on EVEREST MEDICINES LIMITED
More recommendations
Chart EVEREST MEDICINES LIMITED
Duration : Period :
Everest Medicines Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVEREST MEDICINES LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 27,57 CNY
Average target price 85,27 CNY
Spread / Average Target 209%
EPS Revisions
Managers and Directors
Kerry Levan Blanchard Chief Executive Officer & Executive Director
Ian Ying Woo President, CFO & Executive Director
Wei Fu Chairman
Jennifer Yang Chief Scientific Officer
Xiaofan Zhang Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
EVEREST MEDICINES LIMITED-50.22%1 283
CSL LIMITED5.12%95 233
WUXI BIOLOGICS (CAYMAN) INC.0.39%56 209
SAMSUNG BIOLOGICS CO.,LTD.8.96%50 311
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.27%32 892